Breaking

MHRA approves new biosimilar●AstraZeneca Q1 results exceed forecast●NICE updates TA guidance for oncology●Roche launches Phase III rare disease trial●FDA grants breakthrough therapy designation●UK Biobank releases genomic dataset●GSK acquires clinical-stage biotech firm●EMA recommends novel gene therapy●MHRA approves new biosimilar●AstraZeneca Q1 results exceed forecast●NICE updates TA guidance for oncology●Roche launches Phase III rare disease trial●FDA grants breakthrough therapy designation●UK Biobank releases genomic dataset●GSK acquires clinical-stage biotech firm●EMA recommends novel gene therapy●

NHS expands abiraterone access for high-risk prostate

NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because

Editorial|4 March 2026

Pharmaceutical

Latest Research & Insights

Expert analysis from pharmaceutical industry leaders

View All Articles→

Research

Microgravity helps find new antimicrobials for superbugs

Microgravity is increasingly recognised as a valuable tool for antimicrobial discovery due to its impact on microbial interactions, competition, and adaptation. Evidence from the International Space S

Editorial·7 May 2026